Kantar Health Oncology Experts and Synix Inc. to Host 8th Annual Seminar in Tokyo
NEW YORK, July 9, 2012—Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, today announced that it will host a seminar highlighting the implications of recent drug approvals and clinical results on the oncology competitive landscape. The seminar is presented in conjunction with Synix Inc., Kantar Health’s partner in Japan.
The seminar, “Oncology Conference Insight: Implications from Recent Clinical Developments,” will take place at Conference Square M+ in Tokyo on Thursday, July 12, from 1 to 5 pm and will be led by Kantar Health oncology specialists Gordon Gochenauer, Director, and Neesha Suvarna, Ph.D., Consultant. The presentation will focus on findings involving drugs in development for the major tumor types in Japan, including:
- Breast Cancer: HER2+ Disease’s “Magic Bullet” and Recent Paradigm-Changing Developments
- Chronic Myelogenous Leukemia (CML): Overcoming Resistance
- Colorectal Cancer: Battle Royale – Best Use of VEGF Pathway Inhibition
- Melanoma: Second Wave and the Rising Tide of Resistance
- Multiple Myeloma: New Twists on Old Options
- Non-Small Cell Lung Cancer (NSCLC): Evolving and Emerging Biomarker Populations
- Ovarian Cancer: The Midas Touch?
- Prostate Cancer: The Rise of Second-Generation Hormone Therapies
- Renal Cell Carcinoma: How to Stand Out in a Crowd
To register for “Oncology Conference Insight: Implications from Recent Clinical Developments,” please visit www.synix.co.jp or contact Kousuke Kitamura, Synix Oncology Market Assessment, at firstname.lastname@example.org.
CancerMPact® is an invaluable oncology decision support tool for market analysis, strategic planning, and identification of commercial opportunities in the U.S., Western Europe, Japan, and China. This tool is composed of web-based integrated modules: Treatment Practices and Evolution (Treatment Architecture, Treatment Evolution, and Emerging Technologies), Patient Metrics, and Monthly Drugs and Regimens.
About Kantar Health (www.kantarhealth.com)
Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.
With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.
For more information on Kantar Health, please contact Paula Paradise, Vice President of Global Marketing, at email@example.com